



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sheena M. Loosmore
Appl'n. No. : 09/577,601
Filed : May 25, 2000
Title : CO-EXPRESSION OF RECOMBINANT PROTEINS
Grp./A.U. : 1648
Examiner : Zachariah Lucas
Docket No. : 1038-1026 MIS/jb
Date : December 2, 2002

#11.
Omdt. B
w/Ext (Eman.)
12/12/02

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

BY COURIER

The Commissioner of Patents
and Trademarks,
Box Amendment
Washington, D.C. 20231,
U.S.A.

12/03/2002 BABRAHA1 00000012 09577601

01 FC:1253

920.00 OP

-Ext. (3 mos.)

12/05/2002 BABRAHA1 00000012 09577601

02 FC:1806

180.00 OP

-IDS fees

AMENDMENT

Sir:

In response to the Office Action of June 4, 2002, please amend the
above-identified application as follows:

In the Specification:

Please replace the paragraph beginning at page 3, line 9, with the following rewritten
paragraph :

"A second family of high molecular weight adhesion proteins has been
identified in about 25% of NTHI and in encapsulated *H. influenzae* strains (refs. 11,
12, 13). The NTHi member of this second family is termed Haemophilus influenzae
adhesin or Hia, and the homologous protein found in encapsulated strains is termed
Haemophilus influenzae surface fibril protein or Hsf. The *hia* gene was originally
cloned from an expression library using convalescent sera from an otitis media
patient, which indicates that it is an important immunogen during disease.
Production of the full-length recombinant Hia protein in *E. coli* appears to be toxic to
the host, so a series of N-terminally truncated proteins was made as described in
[copending] United States Patent No. 6,335,182 and in PCT Patent Application No.

Bid.
cont'd.

11/15